BioMarin Pharmaceutical and Ascendis Pharma have resolved all global patent disputes related to Ascendis's drug Yuviwel, including cases before the U.S. International Trade Commission. Under the agreement, Ascendis will pay BioMarin royalties of 20% on U.S. net sales and 18% on sales in the EU, Brazil, and South Korea until May 2030. This settlement includes licensing BioMarin's patents for Yuviwel's use in treating conditions like achondroplasia and hypochondroplasia, ensuring continued access to the medicine worldwide. The deal allows BioMarin to focus on further innovation in rare genetic diseases while ending ongoing litigation in multiple countries.
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...
Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...
Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...
JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...
